SPECTREM phase IIIb trial: Guselkumab vs placebo in plaque psoriasis

Results of the phase IIIb SPECTREM trial (NCT06039189), evaluating the efficacy and safety of guselkumab vs placebo through Week 16 in 338 patients with low body surface area (BSA) and moderate plaque psoriasis involving ≥1 high-impact site such as the face or scalp, were published by Gold et al. in the British Journal of Dermatology.

Key data: At Week 16, guselkumab vs placebo showed significantly higher rates of Investigator’s Global Assessment (IGA) 0/1 (74.2% vs 12.4%), IGA 0 (40.4% vs 3.5%), Psoriasis Area and Severity Index (PASI) 90 (52.9% vs 6.2%), PASI 100 (32.4% vs 2.7%), and mean percentage improvement from baseline in BSA (80.6% vs 6.1%). 

Key learning: Guselkumab shows high efficacy and safety in patients with low BSA and moderate plaque psoriasis with involvement of high-impact sites. Improvement across multiple skin clearance domains shows the potential of guselkumab across a broad range of patients.